Chong Kun Dang Pharmaceutical Past Earnings Performance
Past criteria checks 6/6
Chong Kun Dang Pharmaceutical has been growing earnings at an average annual rate of 26.9%, while the Pharmaceuticals industry saw earnings growing at 11.5% annually. Revenues have been growing at an average rate of 9.4% per year. Chong Kun Dang Pharmaceutical's return on equity is 24.7%, and it has net margins of 12.8%.
Key information
26.9%
Earnings growth rate
27.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | 9.4% |
| Return on equity | 24.7% |
| Net Margin | 12.8% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Is Chong Kun Dang Pharmaceutical (KRX:185750) Using Too Much Debt?
Oct 24
Investors Aren't Buying Chong Kun Dang Pharmaceutical Corp.'s (KRX:185750) Earnings
Sep 27Does Chong Kun Dang Pharmaceutical (KRX:185750) Deserve A Spot On Your Watchlist?
Sep 08Are Investors Undervaluing Chong Kun Dang Pharmaceutical Corp. (KRX:185750) By 41%?
Jul 30Investors Don't See Light At End Of Chong Kun Dang Pharmaceutical Corp.'s (KRX:185750) Tunnel
Jun 12Chong Kun Dang Pharmaceutical (KRX:185750) Seems To Use Debt Rather Sparingly
May 27A Look At The Fair Value Of Chong Kun Dang Pharmaceutical Corp. (KRX:185750)
Apr 09Does Chong Kun Dang Pharmaceutical (KRX:185750) Have A Healthy Balance Sheet?
Apr 19Here's Why I Think Chong Kun Dang Pharmaceutical (KRX:185750) Is An Interesting Stock
Apr 05Declining Stock and Solid Fundamentals: Is The Market Wrong About Chong Kun Dang Pharmaceutical Corp. (KRX:185750)?
Mar 09Estimating The Fair Value Of Chong Kun Dang Pharmaceutical Corp. (KRX:185750)
Feb 24The Chong Kun Dang Pharmaceutical (KRX:185750) Share Price Is Up 112% And Shareholders Are Boasting About It
Feb 11Is Chong Kun Dang Pharmaceutical Corp. (KRX:185750) An Attractive Dividend Stock?
Jan 27
Does Chong Kun Dang Pharmaceutical (KRX:185750) Have A Healthy Balance Sheet?
Jan 12With EPS Growth And More, Chong Kun Dang Pharmaceutical (KRX:185750) Is Interesting
Dec 28What Kind Of Shareholders Hold The Majority In Chong Kun Dang Pharmaceutical Corp.'s (KRX:185750) Shares?
Dec 09Could The Market Be Wrong About Chong Kun Dang Pharmaceutical Corp. (KRX:185750) Given Its Attractive Financial Prospects?
Nov 24Revenue & Expenses Breakdown
How Chong Kun Dang Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 1,666,522 | 212,788 | 263,894 | 135,628 |
| 31 Mar 24 | 1,665,726 | 202,243 | 260,067 | 134,071 |
| 31 Dec 23 | 1,669,404 | 212,521 | 256,729 | 140,235 |
| 30 Sep 23 | 1,561,851 | 136,097 | 248,213 | 154,620 |
| 30 Jun 23 | 1,542,134 | 119,045 | 244,186 | 165,765 |
| 31 Mar 23 | 1,512,154 | 99,381 | 243,460 | 175,395 |
| 31 Dec 22 | 1,488,345 | 80,953 | 238,933 | 176,325 |
| 30 Sep 22 | 1,453,159 | 70,692 | 244,271 | 167,075 |
| 30 Jun 22 | 1,411,508 | 44,292 | 238,204 | 163,382 |
| 31 Mar 22 | 1,373,018 | 45,096 | 230,303 | 162,135 |
| 31 Dec 21 | 1,343,559 | 42,720 | 220,449 | 163,277 |
| 30 Sep 21 | 1,318,914 | 52,319 | 210,219 | 170,804 |
| 30 Jun 21 | 1,335,066 | 85,116 | 208,748 | 168,378 |
| 31 Mar 21 | 1,321,558 | 88,792 | 202,759 | 159,951 |
| 31 Dec 20 | 1,303,006 | 91,633 | 203,092 | 146,664 |
| 30 Sep 20 | 1,263,965 | 96,316 | 201,910 | 121,208 |
| 30 Jun 20 | 1,186,156 | 75,889 | 208,175 | 111,346 |
| 31 Mar 20 | 1,138,689 | 60,916 | 215,839 | 103,998 |
| 31 Dec 19 | 1,079,338 | 53,882 | 216,015 | 98,624 |
| 30 Sep 19 | 1,046,387 | 51,327 | 220,341 | 89,173 |
| 30 Jun 19 | 1,000,910 | 50,378 | 216,758 | 86,185 |
| 31 Mar 19 | 971,688 | 50,422 | 217,796 | 80,718 |
| 31 Dec 18 | 956,219 | 42,399 | 216,577 | 77,034 |
| 30 Sep 18 | 934,982 | 43,682 | 220,741 | 73,098 |
| 30 Jun 18 | 919,534 | 46,688 | 218,115 | 68,577 |
| 31 Mar 18 | 893,204 | 45,204 | 212,596 | 64,702 |
| 31 Dec 17 | 884,363 | 53,807 | 214,601 | 65,052 |
| 31 Dec 16 | 831,986 | 40,946 | 200,188 | 67,182 |
Quality Earnings: A185750 has high quality earnings.
Growing Profit Margin: A185750's current net profit margins (12.8%) are higher than last year (7.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A185750's earnings have grown significantly by 26.9% per year over the past 5 years.
Accelerating Growth: A185750's earnings growth over the past year (78.7%) exceeds its 5-year average (26.9% per year).
Earnings vs Industry: A185750 earnings growth over the past year (78.7%) exceeded the Pharmaceuticals industry 21.6%.
Return on Equity
High ROE: A185750's Return on Equity (24.7%) is considered high.